WilmerHale Represents Thermo Fisher in its €1.2 Billion Registered Public Offering of Senior Notes

WilmerHale Represents Thermo Fisher in its €1.2 Billion Registered Public Offering of Senior Notes

Client News

WilmerHale represented Thermo Fisher Scientific Inc., a multinational biotechnology product development company, in its public offering of €600 million aggregate principal amount of 1.750% Senior Notes due 2027, priced at 99.190% of principal, and €600 million aggregate principal amount of 2.375% Senior Notes due 2032, priced at 98.940% of principal. The net proceeds of the offering will be used, with the proceeds of the US offering described above, to pay a portion of the purchase price of the previously announced acquisition of QIAGEN N.V. and for general corporate purposes. The offering priced on March 30, 2020 and closed on April 2, 2020.

The team consisted of Erika Robinson, Justin Ochs, Knute Salhus, Julie Hogan Rodgers, Alan Wilson, Jenny Moore and Alex Bernstein.